 |
|
Valvular Abnormalities and Cardiovascular Status Following Exposure to Dexfenfluramine or Phentermine/Fenfluramine
Julius M. Gardin, MD;
Donald Schumacher, MD;
Ginger Constantine, MD;
Kelly D. Davis, MD;
Cyril Leung, MD;
Cheryl L. Reid, MD
JAMA. 2000;283:1703-1709.
Context Fenfluramine and dexfenfluramine were voluntarily withdrawn from the market in September 1997 because of reports of an association with heart valve abnormalities. Studies have been limited by lack of comparison with untreated controls.
Objective To evaluate cardiovascular status and the prevalence of valvular abnormalities, as assessed by clinical cardiovascular parameters and echocardiography, in patients treated for obesity with dexfenfluramine or phentermine/fenfluramine.
Design Reader-blinded controlled study completed in February 1998.
Setting and Participants Twenty-five clinical centers in the United States. Of 1640 enrolled subjects, 1473 were eligible (479 and 455 had taken dexfenfluramine and phentermine/fenfluramine, respectively, continuously for 30 days or more in the previous 14 months, and 539 were untreated matched controls) and provided clinical and echocardiographic data. Mean (SD) age was 47.4 (11.4) years, mean body mass index was 35.0 (7.4) kg/m2, and 74% were women. Mean (SD) duration of therapy was 6.0 (3.3) months (range, 1-18.4 months) in the dexfenfluramine group, and 11.9 (10.4) months (range, 1.4-63 months) in the phentermine/fenfluramine group, while the untreated group had no anorexigen use during the previous 5 years.
Main Outcome Measures Cardiovascular signs and symptoms; echocardiographic evidence of aortic (AR) or mitral (MR) regurgitation according to US Food and Drug Administration (FDA) criteria (AR  mild or MR moderate) and by grade; tricuspid and pulmonic valve regurgitation; and aortic, mitral, and tricuspid valve leaflet mobility and thickness, for treated vs untreated subjects.
Results Cardiovascular signs and symptoms were similar among anorexigen-treated and untreated subjects. Prevalence rates and relative risk (RR) of AR were significantly increased in anorexigen-treated patients and were 8.9% in the dexfenfluramine group (RR, 2.18; 95% confidence interval [CI], 1.32-3.59), 13.7% in the phentermine/fenfluramine group (RR, 3.34; 95% CI, 2.09-5.35), and 4.1% in the untreated group (P<.001). No statistically significant differences in prevalence were observed for MR, thickening or decreased mobility of any valve leaflet, calculated pulmonary artery systolic pressure, or left ventricular ejection fraction. Serious cardiac events (including myocardial infarction, congestive heart failure, or ventricular arrhythmia) occurring at any time were not statistically different in treated and untreated subjects (dexfenfluramine, 9.0%; phentermine/fenfluramine, 4.0%; and untreated, 8.4%); and following anorexigen treatment were uncommon (dexfenfluramine, 2.3%; phentermine/fenfluramine, 2.4%, and untreated, 3.3%, when adjusted for the median start date of anorexigen use).
Conclusions Our data indicate that use of dexfenfluramine and phentermine/fenfluramine is associated with an increase in the prevalence of AR using FDA echocardiographic criteria, but was not associated with an increase in the prevalence of MR using FDA criteria or with serious cardiac events.
Author Affiliations: Division of Cardiology, University of California, Irvine (Drs Gardin, Leung, and Reid); Center for Nutrition & Preventive Medicine, Charlotte, NC (Dr Schumacher); and Wyeth-Ayerst Research, Philadelphia, Pa (Drs Constantine and Davis).
RELATED ARTICLES
Heart Valve Disorders and Appetite-Suppressant Drugs
Hershel Jick
JAMA. 2000;283(13):1738-1740.
EXTRACT
| FULL TEXT
April 5, 2000
JAMA. 2000;283(13):1759-1760.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases
Donnelly
Toxicol Pathol 2008;36:204-217.
ABSTRACT
| FULL TEXT
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism
Poirier et al.
Circulation 2006;113:898-918.
ABSTRACT
| FULL TEXT
Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice
Mekontso-Dessap et al.
Circulation 2006;113:81-89.
ABSTRACT
| FULL TEXT
Cardiovascular Status in Long-Term Survivors of Hodgkin's Disease Treated With Chest Radiotherapy
Adams et al.
JCO 2004;22:3139-3148.
ABSTRACT
| FULL TEXT
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography)
Cheitlin et al.
J Am Coll Cardiol 2003;42:954-970.
FULL TEXT
ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography)
Cheitlin et al.
Circulation 2003;108:1146-1162.
FULL TEXT
Medical Monitoring for Pharmaceutical Injuries: Tort Law for the Public's Health?
Studdert et al.
JAMA 2003;289:889-894.
ABSTRACT
| FULL TEXT
Clinical and Echocardiographic Follow-up of Patients Previously Treated With Dexfenfluramine or Phentermine/Fenfluramine
Gardin et al.
JAMA 2001;286:2011-2014.
ABSTRACT
| FULL TEXT
Toxicity of Over-the-Counter Cough and Cold Medications
Gunn et al.
Pediatrics 2001;108:e52-52.
ABSTRACT
| FULL TEXT
Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety
Glazer
Arch Intern Med 2001;161:1814-1824.
ABSTRACT
| FULL TEXT
Echocardiographic Examination of Women Previously Treated With Fenfluramine: Long-term Follow-up of a Randomized, Double-blind, Placebo-Controlled Trial
Davidoff et al.
Arch Intern Med 2001;161:1429-1436.
ABSTRACT
| FULL TEXT
More on Cardiac Consequences of Diet Pills
JWatch Women's Health 2000;2000:4-4.
FULL TEXT
More on Cardiac Consequences of Diet Pills
JWatch General 2000;2000:3-3.
FULL TEXT
Heart Valve Disorders and Appetite-Suppressant Drugs
Jick
JAMA 2000;283:1738-1740.
FULL TEXT
|
